Shares jumped to $89.65 in pre-market trading Tuesday, even as the broader consumer discretionary sector slipped, signaling that the rally is about Estee Lauder specifically — and the bet that its restructuring is finally translating to bottom-line results. The company is set to release fiscal 2026 fourth-quarter and full-year results Wednesday, August 19, with a management webcast at 8:30 a.m. ET.

• Last Quarter's Blowout Set a High Bar to Clear

In Q3, Estee Lauder posted $0.91 in adjusted earnings per share, crushing the $0.65 Wall Street expected — a 40% surprise — on revenue of $3.71 billion.

Operating margin expanded by 360 basis points (about 3.6 percentage points) to 15%. That beat means investors now enter Q4 expecting the company to maintain momentum. Analysts project Q4 revenue of $3.55 billion, up 4.1% year-over-year, with adjusted EPS of $0.32, up from just $0.09 a year ago. The low bar makes a beat likely — the company has delivered a trailing four-quarter average earnings surprise of 39.1% — but guidance for fiscal 2027 will matter more.

• A $1.75 Billion Restructuring Is Reaching Its Payoff Window

Estee Lauder expanded its restructuring to target up to 10,000 total position reductions, with expected annual savings climbing to as much as $1.2 billion.

The turnaround plan is on track to deliver annual savings "at the high-end" of its original target range. Investors need to hear today whether those cost cuts are fueling reinvestment or merely masking weak underlying demand.

• China Momentum Is the Swing Factor

In Mainland China, the company estimated it outperformed the prestige beauty market for a third consecutive quarter with high single-digit retail sales growth.

Fragrance was the standout category, with organic sales rising 10%. Whether China accelerated or stalled in Q4 will likely dictate the stock's direction after the call.

• The Stock Remains Far Below Its Highs, Keeping the Risk-Reward Debate Alive

The 52-week range spans from $66.22 to $121.64 — meaning shares sit roughly in the lower third despite three consecutive earnings beats. Weak organic sales growth and earnings declining faster than revenue over the past three years have dampened confidence in a full recovery.

Management guided full-year fiscal 2026 adjusted EPS of $2.35 to $2.45 and previewed fiscal 2027 net sales growth of 3% to 5%. Today's report will either validate or puncture the turnaround thesis.